STOCK TITAN

Nanoviricides - NNVC STOCK NEWS

Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.

Nanoviricides, Inc. (NNVC) is a clinical-stage biopharmaceutical company pioneering antiviral therapies using proprietary nanomedicine technology. This page serves as the definitive source for verified news and official updates regarding the company's innovative drug development programs.

Investors and researchers will find comprehensive coverage of NNVC's progress including clinical trial developments, regulatory milestones, and strategic partnerships. Our curated collection features press releases on lead candidate NV-387's advancement through clinical studies, updates on broad-spectrum antiviral research, and collaborations advancing nanoviricide platforms.

Key content categories include scientific breakthroughs in host-mimetic nanotechnology, FDA regulatory communications, financial reporting disclosures, and analysis of NNVC's position within the antiviral therapeutics market. All materials are sourced directly from company filings and authorized statements to ensure reliability.

Bookmark this page for streamlined access to NNVC's latest developments in nanoscale antiviral solutions. Check regularly for updates on clinical programs targeting respiratory viruses, herpes-related infections, and other viral pathogens through NNVC's novel therapeutic approach.

Rhea-AI Summary
NanoViricides, Inc. (NNVC) successfully completed the Phase 1a/1b Clinical Trial of NV-CoV-2, reporting no adverse events. NV-387, the active ingredient, demonstrated excellent safety and broad-spectrum antiviral activity. The results indicate a promising potential for rapid response to pandemics and treatment of viral infections. The trial was managed by Karveer Meditech Pvt. Ltd. in India and conducted at Mahatma Gandhi Mission's Medical College & Hospital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.35%
Tags
-
Rhea-AI Summary
NanoViricides, Inc. (NNVC) to present at Biotech Showcase 2024, highlighting successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies drug products containing the novel antiviral nanomachine NV-387, with broad-spectrum antiviral activity across multiple virus families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
conferences
-
Rhea-AI Summary
NanoViricides, Inc. (NNVC) reported the successful completion of the Single-Ascending Dose part of the Phase 1a/1b Human Clinical Trial of NV-CoV-2, a broad-spectrum antiviral drug. The drug contains the nanoviricide active agent, NV-387, which has shown strong antiviral activity against coronaviruses, RSV, and Smallpox. The Phase 1a trial in healthy volunteers was completed with no adverse events found. Recruitment for the Multiple-Ascending Dose part was also completed. NV-387 has shown broad-spectrum antiviral activity across multiple virus families, addressing an unmet medical need for a safe and effective antiviral drug. The drug has the potential to revolutionize antiviral treatment and addresses large market sizes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.73%
Tags
Rhea-AI Summary
NanoViricides, Inc. (NYSE American: NNVC) - Quarterly Report on Form 10-Q filed, Financial Status, Liquidity Improvement, Drug Pipeline, Platform Technology Expansion, and Market Potential
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.7%
Tags
-
Rhea-AI Summary
NanoViricides, Inc. (AMEX:NNVC) reports that its broad-spectrum antiviral drug candidate, NV-387, was highly effective in an animal model for MPox and Smallpox virus infections. NV-387, currently in Phase 1a/1b human clinical trials for COVID-19 indication in India, has shown strong activity against Seasonal Coronaviruses, SARS-CoV-2, and Respiratory Syncytial Virus (RSV). The drug is designed to mimic a host cell membrane bearing 'Sulfated Proteoglycans' ('S-PG') family of virus attachment receptors, providing a broad spectrum of antiviral activity. Oral NV-387 treatment led to a significant increase in survival lifespan in animal models, indicating its relative effectiveness compared to other drugs. The company believes that NV-387 has the potential to revolutionize the fight against viruses, similar to how antibiotics revolutionized the fight against bacterial infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.67%
Tags
-
Rhea-AI Summary
NanoViricides to present at PODD Conference and highlights the potential of its antiviral drug candidate NV-387
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
partnership conferences
Rhea-AI Summary
NanoViricides reports successful progress in Phase 1a/1b clinical trial of NV-CoV-2 antiviral drug
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.75%
Tags
-
Rhea-AI Summary
NanoViricides, Inc. reports strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV. NV-387 is expected to advance into Phase II human clinical trials for RSV treatment, which will significantly speed up the development of the RSV drug, save costs, and improve ROI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.64%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
Nanoviricides

NYSE:NNVC

NNVC Rankings

NNVC Stock Data

20.80M
15.07M
3.63%
9.36%
0.9%
Biotechnology
Pharmaceutical Preparations
Link
United States
SHELTON